Bifogade filer
RaySearch Press Release July 21, 2025
AKSM-RaySearch 1200x620
Kurs
+0,42%
Likviditet
21,0 MSEK
Prenumeration
Kalender
| Est. tid* | ||
| 2026-02-12 | 07:50 | Bokslutskommuniké 2025 |
| 2025-11-07 | 07:50 | Kvartalsrapport 2025-Q3 |
| 2025-08-08 | - | Kvartalsrapport 2025-Q2 |
| 2025-05-23 | - | X-dag ordinarie utdelning RAY B 3.00 SEK |
| 2025-05-22 | - | Årsstämma |
| 2025-05-09 | - | Kvartalsrapport 2025-Q1 |
| 2025-02-21 | - | Bokslutskommuniké 2024 |
| 2024-11-08 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-16 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-23 | - | X-dag bonusutdelning RAY B 1.3 |
| 2024-05-23 | - | X-dag ordinarie utdelning RAY B 0.70 SEK |
| 2024-05-22 | - | Årsstämma |
| 2024-05-17 | - | Kvartalsrapport 2024-Q1 |
| 2024-02-23 | - | Bokslutskommuniké 2023 |
| 2023-11-17 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-25 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-26 | - | X-dag ordinarie utdelning RAY B 0.00 SEK |
| 2023-05-25 | - | Årsstämma |
| 2023-05-17 | - | Kvartalsrapport 2023-Q1 |
| 2023-02-28 | - | Bokslutskommuniké 2022 |
| 2022-11-29 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-29 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-27 | - | X-dag ordinarie utdelning RAY B 0.00 SEK |
| 2022-05-25 | - | Årsstämma |
| 2022-05-18 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-23 | - | Bokslutskommuniké 2021 |
| 2021-11-18 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-25 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-27 | - | X-dag ordinarie utdelning RAY B 0.00 SEK |
| 2021-05-26 | - | Årsstämma |
| 2021-05-05 | - | Kvartalsrapport 2021-Q1 |
| 2021-02-23 | - | Bokslutskommuniké 2020 |
| 2020-11-18 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-26 | - | Kvartalsrapport 2020-Q2 |
| 2020-07-01 | - | X-dag ordinarie utdelning RAY B 0.00 SEK |
| 2020-06-30 | - | Årsstämma |
| 2020-05-05 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-14 | - | Bokslutskommuniké 2019 |
| 2019-11-14 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-20 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-22 | - | X-dag ordinarie utdelning RAY B 0.00 SEK |
| 2019-05-21 | - | Årsstämma |
| 2019-05-09 | - | Kvartalsrapport 2019-Q1 |
| 2019-02-20 | - | Bokslutskommuniké 2018 |
| 2018-11-15 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-23 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-31 | - | X-dag ordinarie utdelning RAY B 0.00 SEK |
| 2018-05-29 | - | Årsstämma |
| 2018-05-09 | - | Kvartalsrapport 2018-Q1 |
| 2018-02-15 | - | Bokslutskommuniké 2017 |
| 2017-11-22 | - | Kvartalsrapport 2017-Q3 |
| 2017-08-24 | - | Kvartalsrapport 2017-Q2 |
| 2017-05-24 | - | X-dag ordinarie utdelning RAY B 0.00 SEK |
| 2017-05-23 | - | Årsstämma |
| 2017-05-19 | - | Kvartalsrapport 2017-Q1 |
| 2017-02-17 | - | Bokslutskommuniké 2016 |
| 2016-11-18 | - | Kvartalsrapport 2016-Q3 |
| 2016-08-25 | - | Kvartalsrapport 2016-Q2 |
| 2016-05-18 | - | X-dag ordinarie utdelning RAY B 0.25 SEK |
| 2016-05-17 | - | Årsstämma |
| 2016-05-12 | - | Kvartalsrapport 2016-Q1 |
| 2016-02-18 | - | Bokslutskommuniké 2015 |
| 2015-11-25 | - | Kvartalsrapport 2015-Q3 |
| 2015-08-28 | - | Kvartalsrapport 2015-Q2 |
| 2015-05-29 | - | X-dag ordinarie utdelning RAY B 0.00 SEK |
| 2015-05-28 | - | Årsstämma |
| 2015-05-08 | - | Kvartalsrapport 2015-Q1 |
| 2015-02-12 | - | Bokslutskommuniké 2014 |
| 2014-11-27 | - | Kvartalsrapport 2014-Q3 |
| 2014-08-27 | - | Kvartalsrapport 2014-Q2 |
| 2014-05-28 | - | X-dag ordinarie utdelning RAY B 0.00 SEK |
| 2014-05-27 | - | Årsstämma |
| 2014-05-16 | - | Kvartalsrapport 2014-Q1 |
| 2014-02-13 | - | Bokslutskommuniké 2013 |
| 2013-11-27 | - | Kvartalsrapport 2013-Q3 |
| 2013-08-28 | - | Kvartalsrapport 2013-Q2 |
| 2013-05-23 | - | X-dag ordinarie utdelning RAY B 0.00 SEK |
| 2013-05-22 | - | Årsstämma |
| 2013-05-16 | - | Kvartalsrapport 2013-Q1 |
| 2013-02-14 | - | Bokslutskommuniké 2012 |
| 2012-11-16 | - | Kvartalsrapport 2012-Q3 |
| 2012-08-28 | - | Kvartalsrapport 2012-Q2 |
| 2012-05-31 | - | X-dag ordinarie utdelning RAY B 0.00 SEK |
| 2012-05-30 | - | Årsstämma |
| 2012-05-23 | - | Kvartalsrapport 2012-Q1 |
| 2012-02-16 | - | Bokslutskommuniké 2011 |
| 2011-11-24 | - | Kvartalsrapport 2011-Q3 |
| 2011-05-26 | - | X-dag ordinarie utdelning RAY B 0.50 SEK |
| 2011-05-25 | - | Årsstämma |
| 2011-05-04 | - | Kvartalsrapport 2011-Q1 |
| 2011-02-18 | - | Bokslutskommuniké 2010 |
| 2010-11-12 | - | Kvartalsrapport 2010-Q3 |
| 2010-08-27 | - | Kvartalsrapport 2010-Q2 |
| 2010-05-26 | - | X-dag ordinarie utdelning RAY B 0.50 SEK |
| 2010-05-25 | - | Årsstämma |
| 2010-05-11 | - | Kvartalsrapport 2010-Q1 |
| 2009-11-20 | - | Kvartalsrapport 2009-Q3 |
| 2009-08-27 | - | Kvartalsrapport 2009-Q2 |
| 2009-05-27 | - | X-dag ordinarie utdelning RAY B 0.00 SEK |
| 2009-05-26 | - | Årsstämma |
| 2009-05-15 | - | Kvartalsrapport 2009-Q1 |
| 2008-06-25 | - | Split RAY B 1:3 |
| 2003-06-10 | - | Split RAY B 20:1 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Mid Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
ART will be a multidisciplinary center serving the central coast of California. The center is one of more than 20 freestanding radiotherapy centers AKSM/Oncology has created in partnership with various physician groups across the USA.
ART has acquired the TrueBeam machine through Radiology Oncology Systems (ROS), a collaboration partner of RaySearch.
RayCare 2024A, which is now market cleared in the U.S., includes interoperability with all Varian TrueBeam linear accelerators. RayCare 2024A also provides a fully integrated workflow from treatment prescription to treatment delivery. Further, the system is deeply integrated with RayStation, bringing efficiency and safety into the clinical workflow by reducing the number of manual actions required. RayStation will provide the center with treatment planning technology such as 3D planning, IMRT, VMAT, electron beam radiation therapy, and deformable registration.
Scott Neal, President of AKSM/Oncology and Board Member at Advanced Radiation Therapeutics: “We are pleased to partner with RaySearch to provide all oncology information and treatment planning systems for our new state-of-the-art Radiation Therapy Center currently under development in San Luis Obispo, CA. RaySearch is at the forefront of innovation in this field, and we look forward to collaborating in our shared commitment to advancing patient care and improving outcomes for our patients.”
Johan Löf, founder and CEO, RaySearch: “I am excited to see the RayCare extension gaining traction in the U.S. and I believe that RaySearch’s integrated treatment planning and oncology information system present a compelling solution for all types of radiotherapy centers. I am convinced that by integrating RayStation and RayCare with TrueBeam, Advanced Radiation Therapeutics will achieve greater efficiency and, ultimately, improved patient care."
The order was received in the second quarter of 2025. Revenue is expected to be recognized over the next eight months leading up to the department go-live.
For more information, please contact:
Johan Löf, founder and CEO, RaySearch Laboratories AB (publ)
Telephone: + 46 (0) 8 510 530 00
johan.lof@raysearchlabs.com
About Advanced Radiation Therapeutics
Advanced Radiation Therapeutics (ART) is proud to be part of a distinguished group of oncology care providers uniting under one roof at a new, state-of-the-art cancer center in San Luis Obispo. In partnership with Dignity Health, this collaborative initiative is designed to enhance the continuity and quality of care for cancer patients across the region. By co-locating with multiple oncology specialties in a single, integrated facility, ART is well-positioned to further its mission: delivering the highest standard of coordinated, patient-centered care on the Central Coast.
“Together, we are creating a healing environment where every patient receives the personalized care they deserve – delivered promptly and compassionately in a comprehensive, advanced cancer center,”
— Edwin Hayashi, MD, General Surgeon and Chair of ART’s Cancer Committee
About RaySearch
RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation®* treatment planning system (TPS) and the oncology information system (OIS) RayCare®*. The most recent additions to the RaySearch product line are RayIntelligence® and RayCommand®*. RayIntelligence is an oncology analytics system (OAS) which enables cancer clinics to collect, structure and analyze data. RayCommand, a treatment control system (TCS), is designed to link the treatment machine and the treatment planning and oncology information systems.
RaySearch’s software has been sold to over 1,100 clinics in 47 countries. The company was founded in 2000 as a spin-off from the Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003. More information is available at raysearchlabs.com.
About RayStation
RayStation®* is a flexible, innovative treatment planning system, chosen by many leading cancer centers worldwide. It combines unique features such as unmatched adaptive therapy capabilities, multi-criteria optimization, market-leading algorithms for treatment plan optimization for HDR brachytherapy and external beam therapy with photons, electrons, and protons, as well as helium and carbon ions. RayStation supports a wide range of treatment machines, providing one control center for all treatment planning needs and ensuring centers get greater value from existing equipment. RayStation also seamlessly integrates with RayCare®*. By harmonizing the treatment planning, the care of cancer patients worldwide is improved.
About RayCare
The RayCare®* oncology information system (OIS) is designed to support the many complex logistical challenges faced by today’s oncology clinics. RayCare is closely integrated with RayStation®* and provides seamless access to all the powerful planning tools in RayStation and RayCommand®. The system efficiently coordinates activities in radiation therapy and offers advanced features for clinical workflow automation, and adaptive radiation therapy. RayCare responds to the demand from clinics for a more user-friendly and workflow-oriented information system that can support the cancer care of the future.
* Subject to regulatory clearance in some markets.